ArticleScientific reports2026
Phosphorylated filamin-A at serine 1459 from plasma-derived small extracellular vesicles as a promising biomarker for high-risk adenoma and colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection can reduce CRC mortality by more than 90%. Circulating small extracellular vesicles (sEVs) are emerging as promising biomarkers for CRC, but their role in detecting precancerous lesions remains unclear. Herein, parallel proteomic and phosphoproteomic analyses of plasma-derived sEVs were performed in healthy subjects with negative colonoscopy, patients with high-risk adenoma (HRA) and patients with CRC. A total of 139 phosphorylation sites on 52 proteins were identified, among which 16 phosphorylation sites on 12 sEV proteins showed significant changes (≥ 2-fold) with 90% confidence in site localization. Web-based validation demonstrated that the phosphorylation level of sEV-derived filamin-A at serine 1459 (pFLNA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.